Sharemaestro Newsreel

Exagen Q2 Earnings Call Highlights

Exagen Inc (XGN) reported record quarterly revenue of $19.9 million in Q2 2026, marking a 16% year-over-year increase, driven by record AVISE test volume and Pharma Services revenue. The company also significantly narrowed its adjusted EBITDA loss to $0.1 million and raised its full-year …

Natera Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Natera, Inc. (NASDAQ: NTRA) and reminds investors of the June 27, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges Natera made false and misleading statements …

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

Faruqi & Faruqi, LLP is investigating potential securities claims against Grail, Inc. (NASDAQ: GRAL) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is August 4, 2026. The lawsuit alleges that Grail made …

Amundi Buys 57,288 Shares of Medpace Holdings, Inc. $MEDP

Amundi increased its stake in Medpace Holdings, Inc. (MEDP) by 1,487.6% in the first quarter, acquiring 57,288 additional shares and bringing its total holdings to 61,139 shares valued at $29.4 million. Despite institutional ownership of 77.98% and strong quarterly earnings, analysts maintain a "Hold" …

Earnings call transcript: Revvity beats Q2 2026 estimates, but shares fall premarket

Revvity (RVTY) announced strong Q2 2026 results, exceeding adjusted EPS and revenue estimates, driven by organic growth, wider margins, and increased demand linked to AI. Despite the beat and raised full-year guidance for organic growth, operating margin, and EPS, the company's shares fell in …

PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI

The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Personalis, Inc. (Nasdaq: PSNL) to Tempus AI, Inc. for $16.25 per share. The investigation comes after Tempus shares fell post-announcement, leading to a decrease in Personalis's …

Don't Ignore The Insider Selling In IQVIA Holdings

An executive at IQVIA Holdings recently sold US$1.2m worth of stock, reducing their total holding by 19%. While this is a significant sale, it occurred at a price close to the current share price, which is less concerning than sales at lower prices. The …

IDEXX Laboratories jumps 5% on strong results, raised guidance (IDXX:NASDAQ)

IDEXX Laboratories (IDXX) shares rose over 5% after the company reported strong second-quarter results and provided upbeat full-year earnings guidance. The veterinary diagnostics company posted an adjusted EPS of $4.07 for the quarter. This positive performance has led to a significant increase in its …

SOTERA HEALTH COMPANY (SHC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of The Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Sotera Health Company (SHC)

Bernstein Liebhard LLP has issued a shareholder class action alert for investors in Sotera Health Company (SHC), reminding them of the March 27, 2023 deadline to file a lead plaintiff motion. The lawsuit alleges violations of securities laws related to misleading representations about Sotera's …

Earnings call transcript: Exagen tops Q2 2026 estimates, shares jump 20%

Exagen (XGN) reported strong Q2 2026 results, surpassing Wall Street expectations with record revenue of $19.9 million and narrowing its adjusted EBITDA loss to $0.1 million. The autoimmune-testing company also raised its full-year 2026 revenue guidance to $72 million-$75 million, driven by increased test …

Charles River Laboratories International Inc. stock rises Tuesday, still underperforms market

Shares of Charles River Laboratories International Inc. (CRL) rose 1.41% on Tuesday, closing at $234.12. This increase broke a four-day losing streak for the company's stock. Despite the rise, the stock still underperformed the broader market, with the S&P 500 Index and Dow Jones …

Revvity Inc. stock underperforms Tuesday when compared to competitors

Revvity Inc. (RVTY) stock fell 3.32% on Tuesday, closing at $111.39, even as the broader market, including the S&P 500 Index and Dow Jones Industrial Average, saw significant gains. The company's stock was also 5.84% below its 52-week high reached on January 22nd.

ICON plc plans private note offering to refinance debt

ICON plc announced a private offering of senior notes to refinance its debt, aiming to repay its Bridge Secured Credit Facility, existing term loans, and redeem its 5.809% Senior Secured Notes due 2027. This strategic move is designed to simplify the company's balance sheet …

Is Exagen Inc (XGN) Worth the Price After Q2 Earnings? Revenue Hits $19.9M but GF Score Indicates 56.3% Overvalued

Exagen Inc (XGN) reported Q2 2026 revenue of $19.9 million, surpassing analyst estimates and marking a 16% increase year-over-year, with a reduced net loss of $3.2 million. Despite strong growth and improved operational efficiency, GuruFocus rates the stock as 56.3% overvalued at its current …

New leaders named at Masimo, Danaher after deal closes

Tim Benner has been appointed president of Masimo Corp. following a deal closure. Concurrently, Julie Sawyer Montgomery will assume the roles of president and CEO of Danaher Corp. starting in October. The article highlights these key executive changes at both companies.

Labcorp Holdings Inc. stock rises Tuesday, still underperforms market

Labcorp Holdings Inc. (LH) stock increased by 1.60% on Tuesday, closing at $312.34. Despite this rise, the stock still underperformed the broader market, as both the S&P 500 Index and the Dow Jones Industrial Average saw larger gains. This marked the end of a …

Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last

IQVIA Holdings Inc. (IQV) shares surged 13% in a week driven by better-than-expected quarterly results, strong bookings, and a raised full-year outlook. While the company's financial performance was robust, with increased earnings and revenues, and improved revenue visibility through record bookings, its elevated leverage …

IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors

IQVIA Holdings Inc. stock (IQV) fell 2.21% to $228.20 on Tuesday, marking its fourth consecutive day of losses. This underperformance occurred despite a positive trading session for the broader market, with both the S&P 500 Index and Dow Jones Industrial Average seeing significant gains.

Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?

IQVIA Holdings Inc. (IQV) is experiencing improved growth in clinical research and commercial services, driven by its proprietary data assets. However, the company faces financial risks due to high debt, limited short-term liquidity, and continued share buybacks. While its data advantage and growing revenue …

Danaher Corp. stock outperforms competitors despite losses on the day

Danaher Corp. (DHR) shares fell 1.38% to $194.78 on Tuesday, despite a positive trading session for the broader stock market, with the S&P 500 and Dow Jones Industrial Average both rising. The company's stock closed 19.78% below its 52-week high of $242.80. This indicates …

Danaher Beat Earnings Estimates, so Why Are Investors Still Concerned About Growth?

Danaher Corporation reported mixed second-quarter results, beating earnings estimates and raising adjusted EPS guidance, but experiencing weaker-than-expected bioprocessing revenue and a reduced full-year core revenue growth outlook. This has led to investor concern despite strong underlying demand in its Life Sciences business. Investors are …

VCYT Maintained by Stephens & Co. -- Price Target Lowered to $55

Stephens & Co. has maintained an Overweight rating for Veracyte (VCYT) but lowered its price target from $68.00 to $55.00. The stock is currently considered 16.3% overvalued by GuruFocus, trading at $44.84 against a GF Value™ of $38.56, despite a strong GF Score™ of …

Medicare Coverage Granted for Veracyte’s Test for Muscle-Invasive Bladder Cancer

Veracyte Inc.'s TrueMRD Monitoring Test has received Medicare coverage for recurrence monitoring in patients with muscle-invasive bladder cancer (MIBC) following definitive treatment. This marks Veracyte's first molecular residual disease (MRD) offering and the only commercially available whole-genome MRD test, significantly expanding its reach into …

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

Johnson Fistel, PLLP is investigating Myriad Genetics, Inc. (MYGN) for potential federal securities law violations after the company reported an 11% year-over-year revenue decline and reduced its annual guidance. This decline was attributed to issues like lower reimbursement and unfavorable estimate changes, leading to …

Sotera Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Sotera Health Company (NASDAQ: SHC) and reminds investors of the March 27, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Sotera made false and …

Revvity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 05, 2026

Revvity, Inc. announced its financial results for the second quarter and six months ended July 05, 2026. For the second quarter, sales increased to $729.69 million from $720.28 million year-over-year, while net income slightly decreased to $51.82 million. Diluted EPS for the quarter was …

Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results

Exagen Inc. (NASDAQ: XGN) lifts Q2 2026 revenue to $19.9M

Exagen Inc. reported a significant increase in Q2 2026 revenue to $19.9 million, up from $17.2 million a year earlier, primarily driven by its AVISE® CTD autoimmune diagnostic test. The company narrowed its net loss to $3.2 million and improved its operating loss to …

EXAGEN INC. Q2 2026: Revenue $19.94M, EPS $(0.13) — 10-Q Summary

EXAGEN INC. (XGN) reported its Q2 2026 financial results, showing revenue of $19.94 million and a diluted EPS of $(0.13). The company achieved a narrower net loss of $3.2 million compared to $4.44 million in the prior year, driven by improved margins, higher test …

Exagen Q2 2026 slides: record revenue, stock surges 36%

Exagen Inc. reported record revenue of $19.9 million for Q2 2026, marking 16% year-over-year growth and exceeding analyst expectations. The company's stock surged 35.9% following the announcement, driven by strong quarterly performance and raised full-year guidance. Exagen is nearing profitability, with adjusted EBITDA loss …

Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors

The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Grail, Inc. (NASDAQ: GRAL) who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made misleading statements and concealed material adverse facts regarding …

Twist Bioscience Corp stock hits 52-week high at 106.58 USD

Twist Bioscience Corp (TWST) reached a 52-week high of $106.58, with its stock currently trading at $103.80. The company has shown a robust 267.22% increase over the past year and recently reported fiscal third-quarter 2026 revenue of $118.4 million, exceeding expectations. Despite the strong …

IDEXX Laboratories Q2 2026 Earnings Call Transcript

IDEXX Laboratories reported strong Q2 2026 financial results, with a 10% revenue increase and a raised full-year outlook. The company highlighted robust growth in CAG Diagnostics, Water, and LPD businesses, driven by innovation, increased diagnostic utilization, and expanding customer

IDEXX Laboratories Announces Second Quarter Results

IDEXX Laboratories reported strong second quarter 2026 results, with revenue growth of 10% and EPS increasing by 18%. The company's Companion Animal Group Diagnostics recurring revenue grew by 11%, driven by innovation and increased diagnostic utilization. IDEXX also narrowed its 2026 revenue guidance and …

NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

NeoGenomics, Inc. (NEO) recently hit a new 52-week high, with its stock up 4.5% in the past month and 34.7% since the start of the year. This outperformance is attributed to strong earnings surprises, with expected EPS growth of 50% for the current fiscal …

Insight Molecular Diagnostics updates financial calendar ahead of quarterly results webinar

Insight Molecular Diagnostics announced updates to its financial calendar, scheduling its Q2 2026 results webinar for August 10, 2026, at 5 p.m. ET. Additionally, management will participate in the Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026. This news brief was …